News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Apricus Biosciences (APRI) Launches Commercialization Arm With Definitive Agreement to Acquire TopoTarget A/S


12/16/2011 10:31:23 AM

SAN DIEGO, Dec. 16, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) announced today a definitive agreement to acquire Topotarget USA, Inc. ("Topotarget USA"), a subsidiary of Topotarget A/S, a public Danish company ("Topotarget A/S"). Topotarget USA owns Totect (Dexrazoxane HCl), the only drug approved by the FDA to treat a potentially serious complication of cancer therapy—the leakage of chemotherapy drugs from veins into surrounding tissues. This complication is known as anthracycline extravasation, and can lead to infections and tissue death.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES